Table 1. Clinical Characteristics of Patients (N=37).
| Characteristic | Number of Patients (%) | |
|---|---|---|
| Sex | Female | 18 (49%) |
| Male | 19 (51%) | |
| Histology | Adenocarcinoma | 22 (60%) |
| Adenocarinoma with BAC features | 9 (24%) | |
| Squamous cell carcinoma | 3 (8%) | |
| Poorly differentiated carcinoma | 2 (5%) | |
| Large cell neuroendocrine | 1 (3%) | |
| Ethnicity | White | 25 (68%) |
| African American | 5 (13%) | |
| Asian | 4 (11%) | |
| Hispanic/Latino | 3 (8%) | |
| ECOG performance status | PS 1 | 5 (14%) |
| PS 0 | 32 (86%) | |
| Age | Median age | 61yrs |
| range | 30-85 yrs | |
| No. of prior chemotherapy and targeted regimens | 0 | 0 (0%) |
| 1 | 17 (46%) | |
| 2 | 4 (11%) | |
| 3 | 8 (22%) | |
| 4 | 3 (8%) | |
| 5 | 3 (8%) | |
| 6 | 2 (5%) | |
| Previous therapy | platinum (Cisplatin/Carboplatin) | 33 (89%) |
| Taxane (Docetaxel/Paclitaxel) | 29 (78%) | |
| Erlotinib/Gefitinib | 16 (43%) | |
| Bevacizumab | 15 (40%) | |
| Pemetrexed | 13 (35%) | |